John Gillard, CEO of Trinity Biotech, emphasized that their patented technology is set to disrupt the CGM market, which is expected to surpass $20 billion by 2029. He highlighted the ergonomic ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.

We are developing a CGM system that is not only highly accurate but also disruptively affordable and user-friendly,” said John Gillard, CEO of Trinity Biotech. “The two largest CGM ...

(RTTNews) - Trinity Biotech plc (TRIB), a biotechnology company ... for its next-generation continuous glucose monitoring or CGM system. The findings show approximately 35 percent improvement ...

Shares of Trinity Biotech (NASDAQ:TRIB ... pivotal clinical trial for its next-gen continuous glucose monitoring (CGM) system. Based on data from 30 diabetic patients, Trinity (NASDAQ:TRIB ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...

Trinity announced results from its pre-pivotal clinical trial for continuous glucose monitoring system. The trial results indicated a 25% to 30% improvement in accuracy over earlier CGM sensors.

On the innovation front, Trinity Biotech revealed promising results from a pre-pivotal clinical trial for its continuous glucose monitoring (CGM) system. This breakthrough is expected to provide ...

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market.

Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech ...